Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension

J Am Geriatr Soc. 2010 Jul;58(7):1327-32. doi: 10.1111/j.1532-5415.2010.02905.x. Epub 2010 Jun 1.

Abstract

Objectives: To determine the efficacy of spironolactone (SPIRO) and hydrochlorothiazide (HCTZ) as monotherapy in older patients with hypertension in blood pressure (BP) control and measures of vascular stiffness.

Design: Randomized double-blind trial.

Setting: University teaching hospital.

Participants: Forty-five subjects with hypertension (24 men, 21 women, mean age 69).

Intervention: Six months of HCTZ (n=21) or SPIRO (n=24) therapy titrated to a target systolic BP (SBP) less than 140 mmHg.

Measurements: Baseline (after 4 weeks of antihypertensive drug washout) and 6-month 24-hour ambulatory BP data were obtained. Pulse pressure (PP) was calculated as the difference between 24-hour average SBP and DBP. Pulse wave velocity (PWV) was determined according to noninvasive recordings of carotid and femoral artery pulse waves.

Results: Six months of HCTZ and SPIRO treatment was associated with significant decreases in 24-hour and nocturnal SBP and diastolic BP (DBP) (analysis of variance (ANOVA) P<.001). At 6 months, average 24-hour and nocturnal SBP were lower in the SPIRO than the HCTZ group (P<.001). PP and PWV also decreased significantly with HCTZ and SPIRO treatments (ANOVA P<.001).

Conclusions: Six months of therapy with HCTZ or SPIRO resulted in comparable reductions in 24-hour average and nocturnal SBP and DBP, PP, and PWV in older subjects with hypertension.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Blood Flow Velocity
  • Blood Pressure Monitoring, Ambulatory
  • Double-Blind Method
  • Female
  • Humans
  • Hydrochlorothiazide / therapeutic use*
  • Hypertension / drug therapy*
  • Hypertension / physiopathology*
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Spironolactone / therapeutic use*
  • Treatment Outcome
  • Vasodilation

Substances

  • Antihypertensive Agents
  • Mineralocorticoid Receptor Antagonists
  • Hydrochlorothiazide
  • Spironolactone